<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134432</url>
  </required_header>
  <id_info>
    <org_study_id>AIHA-KA04062-gms</org_study_id>
    <nct_id>NCT01134432</nct_id>
  </id_info>
  <brief_title>Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia</brief_title>
  <official_title>Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The conventional treatment in warm-antibody dependent autoimmune haemolytic anaemia (AIHA) is&#xD;
      high-dose glucocorticoid, but in more than half of the patients, haemolytic activity will&#xD;
      recur after end of treatment or during the gradual reduction in dose of the drug. As a&#xD;
      result, many patients will finally be splenectomized or be treated with long-term&#xD;
      glucocorticoids or other immunosuppressive drugs as azathioprine or cyclophosphamide. Recent&#xD;
      studies have shown however, that some patients will respond to treatment with the chimeric&#xD;
      anti-CD 20 antibody Rituximab and is some cases, the response is permanent. In most of the&#xD;
      studies, Rituximab has been used in refractory disease or at least as second line treatment.&#xD;
      In this study, patients with AIHA are randomized to receive either high-dose prednisolone&#xD;
      with gradual reduction in dose over 2-3 months alone or in combination with Rituximab 375&#xD;
      mg/m2 once a week for 4 weeks. The efficacy of Rituximab will be evaluated by a comparison of&#xD;
      the patients in the two treatment arms. The primary treatment goal is a reduction in the&#xD;
      number of patients who obtain long-term complete or partial remission. The secondary&#xD;
      treatment goal is a reduction in patients who will be splenectomised or receive other&#xD;
      immunosuppressive drugs. Finally a comparison of side effects of the treatments will take&#xD;
      place.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients in each group in complete or partial remission</measure>
    <time_frame>End of treatment and follow-up for 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>End of treatment plus follow-up for 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Anemia, Hemolytic, Autoimmune</condition>
  <arm_group>
    <arm_group_label>Prednisolone + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone + mabthera</intervention_name>
    <description>Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.&#xD;
Mabthera: 375 mg/m2 once a week for four weeks</description>
    <arm_group_label>Prednisolone + Rituximab</arm_group_label>
    <other_name>mabthera equals Rituximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months</description>
    <arm_group_label>Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or over&#xD;
&#xD;
          -  Clinical and biochemical signs of haemolytic anaemia&#xD;
&#xD;
          -  Positive Coombs test with anti-IgG on its own or with anti-CD3d&#xD;
&#xD;
          -  Adequate contraceptive measures (intrauterine device, contraceptive pill or gestagen&#xD;
             deposit) for women of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Performance status &gt; 2&#xD;
&#xD;
          -  Previous treatment with Rituximab&#xD;
&#xD;
          -  Other immune suppressive or anti neoplastic treatment including prednisolone within 3&#xD;
             months&#xD;
&#xD;
          -  Auto immune haemolytic anaemia within 6 months&#xD;
&#xD;
          -  Other serious disease&#xD;
&#xD;
          -  Pregnant women and nursing mothers. Adequate contraceptive measures must be taken for&#xD;
             the duration of the study.&#xD;
&#xD;
          -  Contraindication for treatment with Rituximab, i.e. patients that develop&#xD;
             hypersensitivity/allergy to the contents of the drug or have antibodies against murine&#xD;
             proteins.&#xD;
&#xD;
          -  Active infection which requires antibiotic treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik S Birgens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Haematology (L121), Copenhagen University Hospital Herlev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet - Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Esbjerg Sygehus</name>
      <address>
        <city>Esbjerg</city>
        <zip>DK-6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haderslev Sygehus</name>
      <address>
        <city>Haderslev</city>
        <zip>DK-6100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holstebro Sygehus</name>
      <address>
        <city>Holstebro</city>
        <zip>DK-7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naestved Sygehus</name>
      <address>
        <city>Naestved</city>
        <zip>DK-4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>DK-4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viborg Sygehus</name>
      <address>
        <city>Viborg</city>
        <zip>DK-8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autoimmune hemolytic anemia</keyword>
  <keyword>hemolytic anemia</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Treatment of autoimmune hemolytic anemia</keyword>
  <keyword>warm antibody dependant autoimmune hemolytic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

